Lamivudine + Zidovudine Tablet Franchise in Ahmedabad

HIV Antiretroviral Supplier in Mumbai

Lamicone Z Tablet Distributor in Delhi

Combination ART Tablet Franchise Opportunity in Bangalore

HIV Therapy Tablet Stockist in Hyderabad
Lamivudine + Zidovudine Export & Manufacturing in Chandigarh

Home/Products /lamivudine-150mg-zidovudine-300mg-tablet

Lamicone Z Tablet

Composition : Lamivudine (150mg) + Zidovudine (300mg) Tablet

Dosage Form : Tablet

Packaging Type : in a Bottle

Packaging : 30 Tablets

Price : ₹1/-

Lamicone Z Tablet contains Lamivudine 150mg and Zidovudine 300mg, a highly effective antiretroviral therapy (ART) formulation indicated for the management of HIV infection. It helps in reducing viral replication, controlling viral load, and supporting the immune system in HIV-positive patients.

This combination works synergistically: Lamivudine and Zidovudine inhibit reverse transcriptase at different stages, providing robust suppression of HIV replication. Regular use under medical supervision helps maintain immune function and improves patient outcomes.

For distributors and healthcare suppliers, Lamicone Z Tablet is a high-demand ART product, widely prescribed in HIV clinics, hospitals, and infectious disease centers. The increasing prevalence of HIV and the need for reliable combination therapy ensure continuous market demand.

Adding Lamicone Z Tablet to your antiretroviral and viral suppression segment provides strong opportunities in pharmacies, hospital supply chains, HIV care centers, export markets, and third-party manufacturing. Its proven clinical efficacy, patient adherence, and broad therapeutic application make it a valuable addition for pharmaceutical distribution.

Read More

About the Product

Lamicone Z Tablet contains Lamivudine 150mg and Zidovudine 300mg, a highly effective antiretroviral therapy (ART) formulation indicated for the management of HIV infection. It helps in reducing viral replication, controlling viral load, and supporting the immune system in HIV-positive patients.

This combination works synergistically: Lamivudine and Zidovudine inhibit reverse transcriptase at different stages, providing robust suppression of HIV replication. Regular use under medical supervision helps maintain immune function and improves patient outcomes.

For distributors and healthcare suppliers, Lamicone Z Tablet is a high-demand ART product, widely prescribed in HIV clinics, hospitals, and infectious disease centers. The increasing prevalence of HIV and the need for reliable combination therapy ensure continuous market demand.

Adding Lamicone Z Tablet to your antiretroviral and viral suppression segment provides strong opportunities in pharmacies, hospital supply chains, HIV care centers, export markets, and third-party manufacturing. Its proven clinical efficacy, patient adherence, and broad therapeutic application make it a valuable addition for pharmaceutical distribution.

Patients may experience mild side effects such as headache, nausea, fatigue, or gastrointestinal discomfort. In some cases, more serious side effects like anemia, neutropenia, lactic acidosis, or liver toxicity may occur. Patients should report any unusual or persistent symptoms to their healthcare provider promptly.

Lamicone Z Tablet is indicated for the treatment of HIV-1 infection in adults and adolescents. It helps in controlling viral replication, improving immune system function, and delaying the progression of HIV-related conditions.

Before starting Lamicone Z Tablet, patients should inform their doctor about any history of liver or kidney disease, existing infections, or allergies to medications. Therapy should not be stopped abruptly to avoid viral rebound and potential drug resistance. Regular monitoring of blood counts, liver and kidney function, and viral load is recommended during treatment.

Store Lamicone Z Tablet in a cool, dry place, protected from direct sunlight and moisture. Keep it out of reach of children and ensure the container is properly closed. Do not use the tablet past its expiration date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation